ACW 3.70% 7.8¢ actinogen medical limited

Ann: Actinogen awarded UK Innovation Passport for Xanamem, page-26

  1. 6,434 Posts.
    lightbulb Created with Sketch. 5274
    Hi Thymus,

    All good & it’s actually really good news. I am hopeful that before a Ph3 happens for AD with Xanamem that the FDA will come on board with Accelerated Approval. It’s such a clinically unmet need globally, not just a diagnosis of AD but cognitive impairment in older people also & MH.

    We know the huge benefits of both being an oral drug (more accessible to patients & QOL & care for them vs infusions in a hospital/outpatient setting plus the cost) as well as safety data. I know there is more happening in the AD space, but just WOW on the Biogen nightmare & patients dying on clinical trials from cerebral haemorrhage.

    As you would have read, ILAP Passport is there for good reason, so congratulations to Dr Gourlay & team for securing this. Both NICE & MRHA are involved in granting this, so it’s already a good sign.

    Beats old misery guts & his scotch saying he has no confidence lol! All that crap got put to bed long ago, with biomarkers for AD recently developed & doses…just salty & probably needs to drop a bit of Xanamem in his Scotch himself if he can’t see that the likes of NICE & KOL have found Xanamem & ACW to be worthy of an ILAP Passport.

    Good to see you are still here Thymus.
 
watchlist Created with Sketch. Add ACW (ASX) to my watchlist
(20min delay)
Last
7.8¢
Change
-0.003(3.70%)
Mkt cap ! $219.3M
Open High Low Value Volume
8.0¢ 8.0¢ 7.8¢ $103.7K 1.318M

Buyers (Bids)

No. Vol. Price($)
2 70000 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 564540 4
View Market Depth
Last trade - 10.25am 30/07/2024 (20 minute delay) ?
ACW (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.